Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Laurie Kenvin"'
Autor:
Laurie Kenvin, Ji-Hyun Lee, Shalaka S. Hampras, Kenneth H. Shain, William J. Fulp, Rami S. Komrokji, Martha Olesnyckyj, Najla Al Ali, Alan F. List, Jeffrey E. Lancet, Kate Fisher, Robert Knight, William S. Dalton, Dana E. Rollison, Qiang Xu, Eric Padron
Publikováno v:
Cancer Medicine
The few studies that have examined rates of acute myeloid leukemia (AML) transformation in lenalidomide‐treated myelodysplastic syndrome (MDS) patients have been limited to deletion 5q MDS. The association between lenalidomide and subsequent primar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::436158a7384be3079a54870059a34f4f
https://doi.org/10.1002/cam4.721
https://doi.org/10.1002/cam4.721
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Autor:
Rami S. Komrokji, Rachid Baz, William S. Dalton, Robert Knight, Shalaka S. Hampras, Ji-Hyun Lee, Melissa Alsina, Laurie Kenvin, Taiga Nishihori, Daniel M. Sullivan, Qiang Xu, Marta Olesnyckyj, Dana E. Rollison, William J. Fulp, Kate Fisher, Kenneth H. Shain
Publikováno v:
Leuk Lymphoma
Risk of subsequent primary malignancies (SPMs) associated with lenalidomide therapy in multiple myeloma (MM) patients, outside the context of melphalan-based therapy is not established. We assessed the risk of SPMs in lenalidomide treated MM patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8af84cf6bf133111f38cd793acec245
https://pubmed.ncbi.nlm.nih.gov/27424609
https://pubmed.ncbi.nlm.nih.gov/27424609
Autor:
Jane Jie Lu, James W. Hardin, Jayesh Mehta, Yasir Nagarwala, Laurie Kenvin, Mohit Narang, Robert M. Rifkin, Robert Knight, Howard R. Terebelo, Brian G.M. Durie, Kathleen Toomey, Shankar Srinivasan, Jatin J. Shah, Cristina Gasparetto, Rafat Abonour
Publikováno v:
Leukemialymphoma. 57(9)
Advances in treatment have extended the survival of patients with multiple myeloma (MM),[1] but this increased survival time also increases the potential for developing second primary malignancies ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273d0f8278a5ec17cbd78715ca35d5a0
https://pubmed.ncbi.nlm.nih.gov/26766599
https://pubmed.ncbi.nlm.nih.gov/26766599
Autor:
Ira Gupta, Irina Kline, Courtney D. DiNardo, Eyal C. Attar, Laurie Kenvin, Eytan M. Stein, Ag C Study Investigators, Stéphane de Botton, Amir T. Fathi
Publikováno v:
JAMA Oncology. 4:1106
Importance Enasidenib mesylate, a mutant isocitrate dehydrogenase 2 (IDH2) protein inhibitor that promotes differentiation of leukemic myeloblasts, was recently approved by the US Food and Drug Administration for use in relapsed/refractory (R/R) muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ddb2e86c6af29fa9f83e18afd9c09c
https://doi.org/10.1001/jamaoncol.2017.4695
https://doi.org/10.1001/jamaoncol.2017.4695
Autor:
Courtney D. DiNardo, Irina Kline, Laurie Kenvin, Ira Gupta, Eyal C. Attar, Stéphane de Botton, Eytan M. Stein, Amir T. Fathi
Publikováno v:
Journal of Clinical Oncology. 35:7015-7015
7015 Background: Enasidenib (AG-221), an oral mIDH2 inhibitor, promotes myeloid differentiation of leukemic blasts. Enasidenib treatment (Tx) can result in IDH-inhibitor-associated differentiation syndrome (IDH-DS), with manifestations akin to retino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::755f5d23e1b4b1187ab7c62d06f17074
https://doi.org/10.1200/jco.2017.35.15_suppl.7015
https://doi.org/10.1200/jco.2017.35.15_suppl.7015
Autor:
Robert Vescio, David Irwin, Stephanie F. Williams, Marta Olesnyckyj, Paul G. Richardson, Mohamad A. Hussein, William I. Bensinger, Seema Singhal, James R. Berenson, Jerome B. Zeldis, Zhinuan Yu, Robert Knight, Sundar Jagannath, Laurie Kenvin, Ashraf Badros, Kenneth C. Anderson
Publikováno v:
Blood. 114(4)
Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting. We evaluated the efficacy and safety of lenalidomide monotherapy in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c40a43baad865a95ec27d60d26b94a
https://pubmed.ncbi.nlm.nih.gov/19471019
https://pubmed.ncbi.nlm.nih.gov/19471019
Autor:
Jane Jie Lu, Cristina Gasparetto, Robert M. Rifkin, Kathleen Toomey, Mohit Narang, Rosanna J. Ricafort, Jatin J. Shah, Brian G.M. Durie, Jayesh Mehta, Howard R. Terebelo, Laurie Kenvin, Sachdev P. Thomas, Shankar Srinivasan, Rafat Abonour, James W. Hardin, Yasir Nagarwala
Publikováno v:
Blood. 124:4749-4749
Background: Increased rates of SPM have been observed as newer cancer treatments have improved survival over the past 2 decades (Fraumeni et al. NCI, 2006). Higher incidence of specific types of hematologic SPM following MM, especially acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e85f1c6b418b0b9b34d2fd12635b140
https://doi.org/10.1182/blood.v124.21.4749.4749
https://doi.org/10.1182/blood.v124.21.4749.4749
Autor:
Laurie Kenvin, Najla Al Ali, Marta Olesnyckyj, Ji-Hyun Lee, Shalaka S. Hampras, William S. Dalton, Eric Padron, Jeff E Lancet, Rami S. Komrokji, Kate Fisher, Robert Knight, Kenneth H. Shain, Dana E. Rollison, Alan F. List
Publikováno v:
Blood. 124:413-413
Introduction: Lenalidomide is approved by the FDA for treatment of transfusion-dependent, lower risk, deletion 5q (del(5q)) MDS patients and used widely in practice for non-del(5q) MDS patients with anemia. Recently, subsequent primary malignancies (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e995b29bf253c7da47ecbc0283a9ebcd
https://doi.org/10.1182/blood.v124.21.413.413
https://doi.org/10.1182/blood.v124.21.413.413
Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide
Autor:
Rami S. Komrokji, Laurie Kenvin, William J. Fulp, Marta Olesnyckyj, Rachid Baz, Taiga Nishihori, Kenneth H. Shain, Robert Knight, Kate Fisher, William S. Dalton, Dana E. Rollison, Shalaka S. Hampras, Melissa Alsina, Ji-Hyun Lee, Daniel M. Sullivan
Publikováno v:
Blood. 124:2129-2129
Introduction: The incidence of subsequent primary malignancies (SPM) associated with lenalidomide treatment of multiple myeloma (MM) outside the context of maintenance therapy post-melphalan is unknown. Three clinical trials reported modest, statisti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87ec8b32b900b1ba0d4df5b8585d3ff
https://doi.org/10.1182/blood.v124.21.2129.2129
https://doi.org/10.1182/blood.v124.21.2129.2129
Autor:
Robert Knight, Ruben Niesvizky, Christine Chen, David Irwin, Jerome B. Zeldis, Shaji Kumar, Jonathan Polikoff, Rafat Abonour, Richard A. Gams, David S. Siegel, Laurie Kenvin, Edward A. Stadtmauer, Dennis Pietronigro, Angela Hu, Dale McElveen, Ralph V. Boccia, Donna E. Reece
Publikováno v:
Blood. 108:3556-3556
Background: Lenalidomide (Revlimid®) in combination with dexamethasone was approved in the US on June 29, 2006 for the treatment of subjects with multiple myeloma who had received at least one prior therapy. On February 28, 2005 based upon a positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::557aad78fa9b0cc71abb25658a2e485d
https://doi.org/10.1182/blood.v108.11.3556.3556
https://doi.org/10.1182/blood.v108.11.3556.3556